Crucell Announces PER.C6 Licensing Agreement with Novartis

May 23, 2007
BioPharm International Editors

Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands, www.crucell.com) and Novartis Vaccines and Diagnostics, Inc. (Basel, Switzerland, www.novartis.com), have extended a nonexclusive research license agreement for PER.C6.

Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands, www.crucell.com) and Novartis Vaccines and Diagnostics, Inc. (Basel, Switzerland, www.novartis.com), have extended a nonexclusive research license agreement for PER.C6. The license agreement allows Novartis to use Crucell’s PER.C6 cell technology in manufacturing alphavirus vectors for its vaccine research programs. The PER.C6 technology is a human cell line developed for the development and large-scale manufacture of biopharmaceutical products including vaccines.

Related Content:

News